The Latest Analyst Ratings for 2seventy bio
Portfolio Pulse from Benzinga Insights
In the last quarter, 2seventy bio (NASDAQ:TSVT) received 2 bullish, 2 somewhat bullish, and 1 indifferent analyst rating. The average 12-month price target for the stock, according to 5 analysts, is $22.0, a decrease of 17.29% from the previous average of $26.60.
September 12, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
2seventy bio received mixed analyst ratings in the last quarter, with an average 12-month price target of $22.0, down 17.29% from the previous average.
The mixed analyst ratings indicate uncertainty about the stock's future performance. The decrease in the average price target suggests that analysts have lowered their expectations for the stock, which could potentially impact investor sentiment and the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100